Skip to main content
PMC home page
Microbiological Reviews logoLink to Microbiological Reviews
. 1993 Mar;57(1):34–49. doi: 10.1128/mr.57.1.34-49.1993

Meningococcal lipopolysaccharides: virulence factor and potential vaccine component.

A F Verheul 1, H Snippe 1, J T Poolman 1
PMCID: PMC372900  PMID: 8464406

Abstract

Lipopolysaccharides (LPS) are surface components of the outer membrane of Neisseria meningitidis. Today, 12 different types of meningococcal LPS (immunotypes) are known, of which 3 are prevalent in the western world. The differences between these immunotypes are in the oligosaccharide part of the LPS molecule and consist of small differences in the oligosaccharide structure, the amount and location of phosphoethanolamine groups, and the degree of O acetylation of individual monosaccharides. Although the differences between the various immunotypes are small, they have a profound influence on the immunochemical and immunological properties of these molecules. Furthermore, each individual strain synthesizes a number of different LPS molecules. The expression of the various components (protective epitopes) is influenced by growth conditions and growth phase. Meningococci can endogenously sialyate their LPS, which constitutes one of the mechanisms by which N. meningitidis can evade the response of the human host. Meningococcal LPS play a key role in the induction of septic shock and can probably enhance the invasiveness of meningococcal strains and shield protective epitopes. Therefore, incorporation of (detoxified) LPS or oligosaccharide components derived therefrom might be very beneficial for the efficacy of a vaccine against group B meningococci. An overview of the development of vaccines against group B meningococci is given, and the status and potential of meningococcal LPS-derived (synthetic) oligosaccharide-protein conjugate vaccines are discussed.

Full text

PDF
34

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andersen B. M., Solberg O., Bryn K., Frøholm L. O., Gaustad P., Høiby E. A., Kristiansen B. E., Bøvre K. Endotoxin liberation from Neisseria meningitidis isolated from carriers and clinical cases. Scand J Infect Dis. 1987;19(4):409–419. doi: 10.3109/00365548709021673. [DOI] [PubMed] [Google Scholar]
  2. Andersen B. M., Solberg O. Endotoxin liberation associated with growth, encapsulation and virulence of Neisseria meningitidis. Scand J Infect Dis. 1988;20(1):21–31. doi: 10.3109/00365548809117213. [DOI] [PubMed] [Google Scholar]
  3. Anderson P., Pichichero M., Edwards K., Porch C. R., Insel R. Priming and induction of Haemophilus influenzae type b capsular antibodies in early infancy by Dpo20, an oligosaccharide-protein conjugate vaccine. J Pediatr. 1987 Nov;111(5):644–650. doi: 10.1016/s0022-3476(87)80237-8. [DOI] [PubMed] [Google Scholar]
  4. Apicella M. A., Mandrell R. E., Shero M., Wilson M. E., Griffiss J. M., Brooks G. F., Lammel C., Breen J. F., Rice P. A. Modification by sialic acid of Neisseria gonorrhoeae lipooligosaccharide epitope expression in human urethral exudates: an immunoelectron microscopic analysis. J Infect Dis. 1990 Aug;162(2):506–512. doi: 10.1093/infdis/162.2.506. [DOI] [PubMed] [Google Scholar]
  5. Artenstein M. S., Gold R., Zimmerly J. G., Wyle F. A., Schneider H., Harkins C. Prevention of meningococcal disease by group C polysaccharide vaccine. N Engl J Med. 1970 Feb 19;282(8):417–420. doi: 10.1056/NEJM197002192820803. [DOI] [PubMed] [Google Scholar]
  6. Avery O. T., Goebel W. F. CHEMO-IMMUNOLOGICAL STUDIES ON CONJUGATED CARBOHYDRATE-PROTEINS : II. IMMUNOLOGICAL SPECIFICITY OF SYNTHETIC SUGAR-PROTEIN ANTIGENS. J Exp Med. 1929 Sep 30;50(4):533–550. doi: 10.1084/jem.50.4.533. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. BLACKLOW R. S., WARREN L. Biosynthesis of sialic acids by Neisseria meningitidis. J Biol Chem. 1962 Nov;237:3520–3526. [PubMed] [Google Scholar]
  8. BRANHAM S. E. Milestones in the history of the meningococcus. Can J Microbiol. 1956 May;2(3):175–188. doi: 10.1139/m56-023. [DOI] [PubMed] [Google Scholar]
  9. Beuvery E. C., Miedema F., van Delft R., Haverkamp J. Preparation and immunochemical characterization of meningococcal group C polysaccharide-tetanus toxoid conjugates as a new generation of vaccines. Infect Immun. 1983 Apr;40(1):39–45. doi: 10.1128/iai.40.1.39-45.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Beuvery E. C., vd Kaaden A., Kanhai V., Leussink A. B. Physicochemical and immunological characterization of meningococcal group A polysaccharide-tetanus toxoid conjugates prepared by two methods. Vaccine. 1983 Dec;1(1):31–36. doi: 10.1016/0264-410x(83)90010-5. [DOI] [PubMed] [Google Scholar]
  11. Brandtzaeg P., Kierulf P., Gaustad P., Skulberg A., Bruun J. N., Halvorsen S., Sørensen E. Plasma endotoxin as a predictor of multiple organ failure and death in systemic meningococcal disease. J Infect Dis. 1989 Feb;159(2):195–204. doi: 10.1093/infdis/159.2.195. [DOI] [PubMed] [Google Scholar]
  12. Brandtzaeg P., Mollnes T. E., Kierulf P. Complement activation and endotoxin levels in systemic meningococcal disease. J Infect Dis. 1989 Jul;160(1):58–65. doi: 10.1093/infdis/160.1.58. [DOI] [PubMed] [Google Scholar]
  13. Caugant D. A., Bol P., Høiby E. A., Zanen H. C., Frøholm L. O. Clones of serogroup B Neisseria meningitidis causing systemic disease in The Netherlands, 1958-1986. J Infect Dis. 1990 Oct;162(4):867–874. doi: 10.1093/infdis/162.4.867. [DOI] [PubMed] [Google Scholar]
  14. Caugant D. A., Bøvre K., Gaustad P., Bryn K., Holten E., Høiby E. A., Frøholm L. O. Multilocus genotypes determined by enzyme electrophoresis of Neisseria meningitidis isolated from patients with systemic disease and from healthy carriers. J Gen Microbiol. 1986 Mar;132(3):641–652. doi: 10.1099/00221287-132-3-641. [DOI] [PubMed] [Google Scholar]
  15. Caugant D. A., Mocca L. F., Frasch C. E., Frøholm L. O., Zollinger W. D., Selander R. K. Genetic structure of Neisseria meningitidis populations in relation to serogroup, serotype, and outer membrane protein pattern. J Bacteriol. 1987 Jun;169(6):2781–2792. doi: 10.1128/jb.169.6.2781-2792.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Centers for Disease Control (CDC) Meningococcal disease--United States, 1981. MMWR Morb Mortal Wkly Rep. 1981 Mar 20;30(10):113–115. [PubMed] [Google Scholar]
  17. Cope L. D., Yogev R., Mertsola J., Argyle J. C., McCracken G. H., Jr, Hansen E. J. Effect of mutations in lipooligosaccharide biosynthesis genes on virulence of Haemophilus influenzae type b. Infect Immun. 1990 Jul;58(7):2343–2351. doi: 10.1128/iai.58.7.2343-2351.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Crowe B. A., Wall R. A., Kusecek B., Neumann B., Olyhoek T., Abdillahi H., Hassan-King M., Greenwood B. M., Poolman J. T., Achtman M. Clonal and variable properties of Neisseria meningitidis isolated from cases and carriers during and after an epidemic in The Gambia, West Africa. J Infect Dis. 1989 Apr;159(4):686–700. doi: 10.1093/infdis/159.4.686. [DOI] [PubMed] [Google Scholar]
  19. Cruse J. M., Lewis R. E., Jr Contemporary trends in conjugate vaccine development. Contrib Microbiol Immunol. 1989;10:1–10. [PubMed] [Google Scholar]
  20. Davis C. E., Ziegler E. J., Arnold K. F. Neutralization of meningococcal endotoxin by antibody to core glycolipid. J Exp Med. 1978 Apr 1;147(4):1007–1017. doi: 10.1084/jem.147.4.1007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. DeVoe I. W., Gilchrist J. E. Pili on meningococci from primary cultures of nasopharyngeal carriers and cerebrospinal fluid of patients with acute disease. J Exp Med. 1975 Feb 1;141(2):297–305. doi: 10.1084/jem.141.2.297. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. DeVoe I. W. The meningococcus and mechanisms of pathogenicity. Microbiol Rev. 1982 Jun;46(2):162–190. doi: 10.1128/mr.46.2.162-190.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Dell A., Azadi P., Tiller P., Thomas-Oates J., Jennings H. J., Beurret M., Michon F. Analysis of oligosaccharide epitopes of meningococcal lipopolysaccharides by fast-atom-bombardment mass spectrometry. Carbohydr Res. 1990 Apr 25;200:59–76. doi: 10.1016/0008-6215(90)84182-t. [DOI] [PubMed] [Google Scholar]
  24. Densen P. Interaction of complement with Neisseria meningitidis and Neisseria gonorrhoeae. Clin Microbiol Rev. 1989 Apr;2 (Suppl):S11–S17. doi: 10.1128/cmr.2.suppl.s11. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Devi S. J., Robbins J. B., Schneerson R. Antibodies to poly[(2----8)-alpha-N-acetylneuraminic acid] and poly[(2----9)-alpha-N-acetylneuraminic acid] are elicited by immunization of mice with Escherichia coli K92 conjugates: potential vaccines for groups B and C meningococci and E. coli K1. Proc Natl Acad Sci U S A. 1991 Aug 15;88(16):7175–7179. doi: 10.1073/pnas.88.16.7175. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Dick W. E., Jr, Beurret M. Glycoconjugates of bacterial carbohydrate antigens. A survey and consideration of design and preparation factors. Contrib Microbiol Immunol. 1989;10:48–114. [PubMed] [Google Scholar]
  27. Edwards E. A., Devine L. F., Sengbusch G. H., Ward H. W. Immunological investigations of meningococcal disease. III. Brevity of group C acquisition prior to disease occurrence. Scand J Infect Dis. 1977;9(2):105–110. doi: 10.3109/inf.1977.9.issue-2.09. [DOI] [PubMed] [Google Scholar]
  28. Engebretsen L. F., Kierulf P., Brandtzaeg P. Extreme plasminogen activator inhibitor and endotoxin values in patients with meningococcal disease. Thromb Res. 1986 Jun 1;42(5):713–716. doi: 10.1016/0049-3848(86)90351-8. [DOI] [PubMed] [Google Scholar]
  29. Fattom A., Schneerson R., Szu S. C., Vann W. F., Shiloach J., Karakawa W. W., Robbins J. B. Synthesis and immunologic properties in mice of vaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides conjugated to Pseudomonas aeruginosa exotoxin A. Infect Immun. 1990 Jul;58(7):2367–2374. doi: 10.1128/iai.58.7.2367-2374.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Finne J., Leinonen M., Mäkelä P. H. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet. 1983 Aug 13;2(8346):355–357. doi: 10.1016/s0140-6736(83)90340-9. [DOI] [PubMed] [Google Scholar]
  31. Fox A. J., Jones D. M., Scotland S. M., Rowe B., Smith A., Brown M. R., Fitzgeorge R. G., Baskerville A., Parsons N. J., Cole J. A. Serum killing of meningococci and several other gram-negative bacterial species is not decreased by incubating them with cytidine 5'-monophospho-N-acetyl neuraminic acid. Microb Pathog. 1989 Oct;7(4):317–318. doi: 10.1016/0882-4010(89)90050-8. [DOI] [PubMed] [Google Scholar]
  32. Frasch C. E., Peppler M. S. Protection against group B Neisseria meningitidis disease: preparation of soluble protein and protein-polysaccharide immunogens. Infect Immun. 1982 Jul;37(1):271–280. doi: 10.1128/iai.37.1.271-280.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Frasch C. E. Prospects for the prevention of meningococcal disease: special reference to group B. Vaccine. 1987 Mar;5(1):3–4. doi: 10.1016/0264-410x(87)90002-8. [DOI] [PubMed] [Google Scholar]
  34. Frasch C. E. Vaccines for prevention of meningococcal disease. Clin Microbiol Rev. 1989 Apr;2 (Suppl):S134–S138. doi: 10.1128/cmr.2.suppl.s134. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Frasch C. E., Zollinger W. D., Poolman J. T. Serotype antigens of Neisseria meningitidis and a proposed scheme for designation of serotypes. Rev Infect Dis. 1985 Jul-Aug;7(4):504–510. doi: 10.1093/clinids/7.4.504. [DOI] [PubMed] [Google Scholar]
  36. Gamian A., Beurret M., Michon F., Brisson J. R., Jennings H. J. Structure of the L2 lipopolysaccharide core oligosaccharides of Neisseria meningitidis. J Biol Chem. 1992 Jan 15;267(2):922–925. [PubMed] [Google Scholar]
  37. Gold R., Goldschneider I., Lepow M. L., Draper T. F., Randolph M. Carriage of Neisseria meningitidis and Neisseria lactamica in infants and children. J Infect Dis. 1978 Feb;137(2):112–121. doi: 10.1093/infdis/137.2.112. [DOI] [PubMed] [Google Scholar]
  38. Gold R., Lepow M. L., Goldschneider I., Draper T. F., Gotshlich E. C. Kinetics of antibody production to group A and group C meningococcal polysaccharide vaccines administered during the first six years of life: prospects for routine immunization of infants and children. J Infect Dis. 1979 Nov;140(5):690–697. doi: 10.1093/infdis/140.5.690. [DOI] [PubMed] [Google Scholar]
  39. Goldschneider I., Gotschlich E. C., Artenstein M. S. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med. 1969 Jun 1;129(6):1307–1326. doi: 10.1084/jem.129.6.1307. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Griffiss J. M., Brandt B. L., Broud D. D., Goroff D. K., Baker C. J. Immune response of infants and children to disseminated infections with Neisseria meningitidis. J Infect Dis. 1984 Jul;150(1):71–79. doi: 10.1093/infdis/150.1.71. [DOI] [PubMed] [Google Scholar]
  41. Griffiss J. M. Epidemic meningococcal disease: synthesis of a hypothetical immunoepidemiologic model. Rev Infect Dis. 1982 Jan-Feb;4(1):159–172. doi: 10.1093/clinids/4.1.159. [DOI] [PubMed] [Google Scholar]
  42. Griffiss J. M., Goroff D. K. IgA blocks IgM and IgG-initiated immune lysis by separate molecular mechanisms. J Immunol. 1983 Jun;130(6):2882–2885. [PubMed] [Google Scholar]
  43. Griffiss J. M., O'Brien J. P., Yamasaki R., Williams G. D., Rice P. A., Schneider H. Physical heterogeneity of neisserial lipooligosaccharides reflects oligosaccharides that differ in apparent molecular weight, chemical composition, and antigenic expression. Infect Immun. 1987 Aug;55(8):1792–1800. doi: 10.1128/iai.55.8.1792-1800.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Griffiss J. M., Schneider H., Mandrell R. E., Yamasaki R., Jarvis G. A., Kim J. J., Gibson B. W., Hamadeh R., Apicella M. A. Lipooligosaccharides: the principal glycolipids of the neisserial outer membrane. Rev Infect Dis. 1988 Jul-Aug;10 (Suppl 2):S287–S295. doi: 10.1093/cid/10.supplement_2.s287. [DOI] [PubMed] [Google Scholar]
  45. Halstensen A., Haneberg B., Frøholm L. O., Lehmann V., Frasch C. E., Solberg C. O. Human opsonins to meningococci after vaccination. Infect Immun. 1984 Dec;46(3):673–676. doi: 10.1128/iai.46.3.673-676.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Höppner W., Fischer K., Poschmann A., Paulsen H. Study on the carbohydrate specificity of antibodies formed in rabbits to synthetic glycoproteins with the carbohydrate structure of asialo-glycophorin A. Mol Immunol. 1985 Dec;22(12):1341–1348. doi: 10.1016/0161-5890(85)90055-0. [DOI] [PubMed] [Google Scholar]
  47. Jarvis G. A., Vedros N. A. Sialic acid of group B Neisseria meningitidis regulates alternative complement pathway activation. Infect Immun. 1987 Jan;55(1):174–180. doi: 10.1128/iai.55.1.174-180.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Jennings H. J., Beurret M., Gamian A., Michon F. Structure and immunochemistry of meningococcal lipopolysaccharides. Antonie Van Leeuwenhoek. 1987;53(6):519–522. doi: 10.1007/BF00415511. [DOI] [PubMed] [Google Scholar]
  49. Jennings H. J., Johnson K. G., Kenne L. The structure of an R-type oligosaccharide core obtained from some lipopolysaccharides of Neisseria meningitidis. Carbohydr Res. 1983 Sep 16;121:233–241. doi: 10.1016/0008-6215(83)84020-8. [DOI] [PubMed] [Google Scholar]
  50. Jennings H. J., Lugowski C., Ashton F. E. Conjugation of meningococcal lipopolysaccharide R-type oligosaccharides to tetanus toxoid as route to a potential vaccine against group B Neisseria meningitidis. Infect Immun. 1984 Jan;43(1):407–412. doi: 10.1128/iai.43.1.407-412.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Jennings H. J., Lugowski C. Immunochemistry of groups A, B, and C meningococcal polysaccharide-tetanus toxoid conjugates. J Immunol. 1981 Sep;127(3):1011–1018. [PubMed] [Google Scholar]
  52. Jennings H. J., Roy R., Gamian A. Induction of meningococcal group B polysaccharide-specific IgG antibodies in mice by using an N-propionylated B polysaccharide-tetanus toxoid conjugate vaccine. J Immunol. 1986 Sep 1;137(5):1708–1713. [PubMed] [Google Scholar]
  53. Jennings H. J. The capsular polysaccharide of group B Neisseria meningitidis as a vehicle for vaccine development. Contrib Microbiol Immunol. 1989;10:151–165. [PubMed] [Google Scholar]
  54. John C. M., Griffiss J. M., Apicella M. A., Mandrell R. E., Gibson B. W. The structural basis for pyocin resistance in Neisseria gonorrhoeae lipooligosaccharides. J Biol Chem. 1991 Oct 15;266(29):19303–19311. [PubMed] [Google Scholar]
  55. Kim J. J., Mandrell R. E., Griffiss J. M. Neisseria lactamica and Neisseria meningitidis share lipooligosaccharide epitopes but lack common capsular and class 1, 2, and 3 protein epitopes. Infect Immun. 1989 Feb;57(2):602–608. doi: 10.1128/iai.57.2.602-608.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Kim J. J., Mandrell R. E., Hu Z., Westerink M. A., Poolman J. T., Griffiss J. M. Electromorphic characterization and description of conserved epitopes of the lipooligosaccharides of group A Neisseria meningitidis. Infect Immun. 1988 Oct;56(10):2631–2638. doi: 10.1128/iai.56.10.2631-2638.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  57. Käyhty H., Karanko V., Peltola H., Sarna S., Mäkelä P. H. Serum antibodies to capsular polysaccharide vaccine of group A Neissera meningitidis followed for three years in infants and children. J Infect Dis. 1980 Dec;142(6):861–868. doi: 10.1093/infdis/142.6.861. [DOI] [PubMed] [Google Scholar]
  58. Leinonen M., Frasch C. E. Class-specific antibody response to group B Neisseria meningitidis capsular polysaccharide: use of polylysine precoating in an enzyme-linked immunosorbent assay. Infect Immun. 1982 Dec;38(3):1203–1207. doi: 10.1128/iai.38.3.1203-1207.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  59. Lepow M. L., Beeler J., Randolph M., Samuelson J. S., Hankins W. A. Reactogenicity and immunogenicity of a quadrivalent combined meningococcal polysaccharide vaccine in children. J Infect Dis. 1986 Dec;154(6):1033–1036. doi: 10.1093/infdis/154.6.1033. [DOI] [PubMed] [Google Scholar]
  60. Lepow M. L., Goldschneider I., Gold R., Randolph M., Gotschlich E. C. Persistence of antibody following immunization of children with groups A and C meningococcal polysaccharide vaccines. Pediatrics. 1977 Nov;60(5):673–680. [PubMed] [Google Scholar]
  61. Lifely M. R., Roberts S. C., Shepherd W. M., Esdaile J., Wang Z., Cleverly A., Aulaqi A. A., Moreno C. Immunogenicity in adult males of a Neisseria meningitidis group B vaccine composed of polysaccharide complexed with outer membrane proteins. Vaccine. 1991 Jan;9(1):60–66. doi: 10.1016/0264-410x(91)90318-z. [DOI] [PubMed] [Google Scholar]
  62. Lowell G. H., Smith L. F., Griffiss J. M., Brandt B. L., MacDermott R. P. Antibody-dependent mononuclear cell-mediated antimeningococcal activity. Comparison of the effects of convalescent and postimmunization immunoglobulins G, M, and A. J Clin Invest. 1980 Aug;66(2):260–267. doi: 10.1172/JCI109852. [DOI] [PMC free article] [PubMed] [Google Scholar]
  63. Lund B., Lindberg F., Marklund B. I., Normark S. The PapG protein is the alpha-D-galactopyranosyl-(1----4)-beta-D-galactopyranose-binding adhesin of uropathogenic Escherichia coli. Proc Natl Acad Sci U S A. 1987 Aug;84(16):5898–5902. doi: 10.1073/pnas.84.16.5898. [DOI] [PMC free article] [PubMed] [Google Scholar]
  64. Mandrell R. E., Griffiss J. M., Macher B. A. Lipooligosaccharides (LOS) of Neisseria gonorrhoeae and Neisseria meningitidis have components that are immunochemically similar to precursors of human blood group antigens. Carbohydrate sequence specificity of the mouse monoclonal antibodies that recognize crossreacting antigens on LOS and human erythrocytes. J Exp Med. 1988 Jul 1;168(1):107–126. doi: 10.1084/jem.168.1.107. [DOI] [PMC free article] [PubMed] [Google Scholar]
  65. Mandrell R. E., Kim J. J., John C. M., Gibson B. W., Sugai J. V., Apicella M. A., Griffiss J. M., Yamasaki R. Endogenous sialylation of the lipooligosaccharides of Neisseria meningitidis. J Bacteriol. 1991 May;173(9):2823–2832. doi: 10.1128/jb.173.9.2823-2832.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  66. Mandrell R. E., Lesse A. J., Sugai J. V., Shero M., Griffiss J. M., Cole J. A., Parsons N. J., Smith H., Morse S. A., Apicella M. A. In vitro and in vivo modification of Neisseria gonorrhoeae lipooligosaccharide epitope structure by sialylation. J Exp Med. 1990 May 1;171(5):1649–1664. doi: 10.1084/jem.171.5.1649. [DOI] [PMC free article] [PubMed] [Google Scholar]
  67. Mandrell R. E., Zollinger W. D. Human immune response to meningococcal outer membrane protein epitopes after natural infection or vaccination. Infect Immun. 1989 May;57(5):1590–1598. doi: 10.1128/iai.57.5.1590-1598.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  68. McGuinness B., Barlow A. K., Clarke I. N., Farley J. E., Anilionis A., Poolman J. T., Heckels J. E. Deduced amino acid sequences of class 1 protein (PorA) from three strains of Neisseria meningitidis. Synthetic peptides define the epitopes responsible for serosubtype specificity. J Exp Med. 1990 Jun 1;171(6):1871–1882. doi: 10.1084/jem.171.6.1871. [DOI] [PMC free article] [PubMed] [Google Scholar]
  69. Mertsola J., Cope L. D., Sáez-Llorens X., Ramilo O., Kennedy W., McCracken G. H., Jr, Hansen E. J. In vivo and in vitro expression of Haemophilus influenzae type b lipooligosaccharide epitopes. J Infect Dis. 1991 Sep;164(3):555–563. doi: 10.1093/infdis/164.3.555. [DOI] [PubMed] [Google Scholar]
  70. Michon F., Beurret M., Gamian A., Brisson J. R., Jennings H. J. Structure of the L5 lipopolysaccharide core oligosaccharides of Neisseria meningitidis. J Biol Chem. 1990 May 5;265(13):7243–7247. [PubMed] [Google Scholar]
  71. Moore P. S., Hierholzer J., DeWitt W., Gouan K., Djoré D., Lippeveld T., Plikaytis B., Broome C. V. Respiratory viruses and mycoplasma as cofactors for epidemic group A meningococcal meningitis. JAMA. 1990 Sep 12;264(10):1271–1275. [PubMed] [Google Scholar]
  72. Morrison D. C. Bacterial endotoxins and pathogenesis. Rev Infect Dis. 1983 Sep-Oct;5 (Suppl 4):S733–S747. doi: 10.1093/clinids/5.supplement_4.s733. [DOI] [PubMed] [Google Scholar]
  73. Morrison D. C., Ulevitch R. J. The effects of bacterial endotoxins on host mediation systems. A review. Am J Pathol. 1978 Nov;93(2):526–618. [PMC free article] [PubMed] [Google Scholar]
  74. Mulks M. H., Plaut A. G., Feldman H. A., Frangione B. IgA proteases of two distinct specificities are released by Neisseria meningitidis. J Exp Med. 1980 Nov 1;152(5):1442–1447. doi: 10.1084/jem.152.5.1442. [DOI] [PMC free article] [PubMed] [Google Scholar]
  75. Nairn C. A., Cole J. A., Patel P. V., Parsons N. J., Fox J. E., Smith H. Cytidine 5'-monophospho-N-acetylneuraminic acid or a related compound is the low Mr factor from human red blood cells which induces gonococcal resistance to killing by human serum. J Gen Microbiol. 1988 Dec;134(12):3295–3306. doi: 10.1099/00221287-134-12-3295. [DOI] [PubMed] [Google Scholar]
  76. Paoletti L. C., Kasper D. L., Michon F., DiFabio J., Holme K., Jennings H. J., Wessels M. R. An oligosaccharide-tetanus toxoid conjugate vaccine against type III group B Streptococcus. J Biol Chem. 1990 Oct 25;265(30):18278–18283. [PubMed] [Google Scholar]
  77. Parsons N. J., Curry A., Fox A. J., Jones D. M., Cole J. A., Smith H. The serum resistance of gonococci in the majority of urethral exudates is due to sialylated lipopolysaccharide seen as a surface coat. FEMS Microbiol Lett. 1992 Jan 15;69(3):295–299. doi: 10.1016/0378-1097(92)90663-9. [DOI] [PubMed] [Google Scholar]
  78. Peltola H. Meningococcal disease: still with us. Rev Infect Dis. 1983 Jan-Feb;5(1):71–91. doi: 10.1093/clinids/5.1.71. [DOI] [PubMed] [Google Scholar]
  79. Peltola H., Mäkelä H., Käyhty H., Jousimies H., Herva E., Hällström K., Sivonen A., Renkonen O. V., Pettay O., Karanko V. Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age. N Engl J Med. 1977 Sep 29;297(13):686–691. doi: 10.1056/NEJM197709292971302. [DOI] [PubMed] [Google Scholar]
  80. Peltola H., Safary A., Käyhty H., Karanko V., André F. E. Evaluation of two tetravalent (ACYW135) meningococcal vaccines in infants and small children: a clinical study comparing immunogenicity of O-acetyl-negative and O-acetyl-positive group C polysaccharides. Pediatrics. 1985 Jul;76(1):91–96. [PubMed] [Google Scholar]
  81. Pettersson A., Kuipers B., Pelzer M., Verhagen E., Tiesjema R. H., Tommassen J., Poolman J. T. Monoclonal antibodies against the 70-kilodalton iron-regulated protein of Neisseria meningitidis are bactericidal and strain specific. Infect Immun. 1990 Sep;58(9):3036–3041. doi: 10.1128/iai.58.9.3036-3041.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  82. Poolman J. T., Hopman C. T., Zanen H. C. Colony variants of Neisseria meningitidis strain 2996 (B:2b:P1.2): influence of class-5 outer membrane proteins and lipopolysaccharides. J Med Microbiol. 1985 Apr;19(2):203–209. doi: 10.1099/00222615-19-2-203. [DOI] [PubMed] [Google Scholar]
  83. Poolman J. T. Polysaccharides and membrane vaccines. Adv Biotechnol Processes. 1990;13:57–86. [PubMed] [Google Scholar]
  84. Reingold A. L., Broome C. V., Hightower A. W., Ajello G. W., Bolan G. A., Adamsbaum C., Jones E. E., Phillips C., Tiendrebeogo H., Yada A. Age-specific differences in duration of clinical protection after vaccination with meningococcal polysaccharide A vaccine. Lancet. 1985 Jul 20;2(8447):114–118. doi: 10.1016/s0140-6736(85)90224-7. [DOI] [PubMed] [Google Scholar]
  85. Robbins J. B., Schneerson R. Polysaccharide-protein conjugates: a new generation of vaccines. J Infect Dis. 1990 May;161(5):821–832. doi: 10.1093/infdis/161.5.821. [DOI] [PubMed] [Google Scholar]
  86. Rosenqvist E., Harthug S., Frøholm L. O., Høiby E. A., Bøvre K., Zollinger W. D. Antibody responses to serogroup B meningococcal outer membrane antigens after vaccination and infection. J Clin Microbiol. 1988 Aug;26(8):1543–1548. doi: 10.1128/jcm.26.8.1543-1548.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  87. Ross S. C., Rosenthal P. J., Berberich H. M., Densen P. Killing of Neisseria meningitidis by human neutrophils: implications for normal and complement-deficient individuals. J Infect Dis. 1987 Jun;155(6):1266–1275. doi: 10.1093/infdis/155.6.1266. [DOI] [PubMed] [Google Scholar]
  88. Salih M. A., Danielsson D., Bäckman A., Caugant D. A., Achtman M., Olcén P. Characterization of epidemic and nonepidemic Neisseria meningitidis serogroup A strains from Sudan and Sweden. J Clin Microbiol. 1990 Aug;28(8):1711–1719. doi: 10.1128/jcm.28.8.1711-1719.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  89. Saukkonen K., Leinonen M., Abdillahi H., Poolman J. T. Comparative evaluation of potential components for group B meningococcal vaccine by passive protection in the infant rat and in vitro bactericidal assay. Vaccine. 1989 Aug;7(4):325–328. doi: 10.1016/0264-410x(89)90194-1. [DOI] [PubMed] [Google Scholar]
  90. Schneerson R., Robbins J. B., Parke J. C., Jr, Bell C., Schlesselman J. J., Sutton A., Wang Z., Schiffman G., Karpas A., Shiloach J. Quantitative and qualitative analyses of serum antibodies elicited in adults by Haemophilus influenzae type b and pneumococcus type 6A capsular polysaccharide-tetanus toxoid conjugates. Infect Immun. 1986 May;52(2):519–528. doi: 10.1128/iai.52.2.519-528.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  91. Schneider H., Griffiss J. M., Boslego J. W., Hitchcock P. J., Zahos K. M., Apicella M. A. Expression of paragloboside-like lipooligosaccharides may be a necessary component of gonococcal pathogenesis in men. J Exp Med. 1991 Dec 1;174(6):1601–1605. doi: 10.1084/jem.174.6.1601. [DOI] [PMC free article] [PubMed] [Google Scholar]
  92. Schneider H., Hale T. L., Zollinger W. D., Seid R. C., Jr, Hammack C. A., Griffiss J. M. Heterogeneity of molecular size and antigenic expression within lipooligosaccharides of individual strains of Neisseria gonorrhoeae and Neisseria meningitidis. Infect Immun. 1984 Sep;45(3):544–549. doi: 10.1128/iai.45.3.544-549.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  93. Schwartz B., Moore P. S., Broome C. V. Global epidemiology of meningococcal disease. Clin Microbiol Rev. 1989 Apr;2 (Suppl):S118–S124. doi: 10.1128/cmr.2.suppl.s118. [DOI] [PMC free article] [PubMed] [Google Scholar]
  94. Stephens D. S., Farley M. M. Pathogenic events during infection of the human nasopharynx with Neisseria meningitidis and Haemophilus influenzae. Rev Infect Dis. 1991 Jan-Feb;13(1):22–33. doi: 10.1093/clinids/13.1.22. [DOI] [PubMed] [Google Scholar]
  95. Stephens D. S., Hoffman L. H., McGee Z. A. Interaction of Neisseria meningitidis with human nasopharyngeal mucosa: attachment and entry into columnar epithelial cells. J Infect Dis. 1983 Sep;148(3):369–376. doi: 10.1093/infdis/148.3.369. [DOI] [PubMed] [Google Scholar]
  96. Stephens D. S., Whitney A. M., Melly M. A., Hoffman L. H., Farley M. M., Frasch C. E. Analysis of damage to human ciliated nasopharyngeal epithelium by Neisseria meningitidis. Infect Immun. 1986 Feb;51(2):579–585. doi: 10.1128/iai.51.2.579-585.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  97. Svenson S. B., Lindberg A. A. Coupling of acid labile Salmonella specific oligosaccharides to macromolecular carriers. J Immunol Methods. 1979;25(4):323–335. doi: 10.1016/0022-1759(79)90025-5. [DOI] [PubMed] [Google Scholar]
  98. Söderström C., Braconier J. H., Danielsson D., Sjöholm A. G. Bactericidal activity for Neisseria meningitidis in properdin-deficient sera. J Infect Dis. 1987 Jul;156(1):107–112. doi: 10.1093/infdis/156.1.107. [DOI] [PubMed] [Google Scholar]
  99. Söderström T., Hansson G., Larson G. The Escherichia coli K1 capsule shares antigenic determinants with the human gangliosides GM3 and GD3. N Engl J Med. 1984 Mar 15;310(11):726–727. doi: 10.1056/NEJM198403153101121. [DOI] [PubMed] [Google Scholar]
  100. Tsai C. M., Civin C. I. Eight lipooligosaccharides of Neisseria meningitidis react with a monoclonal antibody which binds lacto-N-neotetraose (Gal beta 1-4GlcNAc beta 1-3Gal beta 1-4Glc). Infect Immun. 1991 Oct;59(10):3604–3609. doi: 10.1128/iai.59.10.3604-3609.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  101. Tsai C. M., Frasch C. E., Mocca L. F. Five structural classes of major outer membrane proteins in Neisseria meningitidis. J Bacteriol. 1981 Apr;146(1):69–78. doi: 10.1128/jb.146.1.69-78.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  102. Tsai C. M., Mocca L. F., Frasch C. E. Immunotype epitopes of Neisseria meningitidis lipooligosaccharide types 1 through 8. Infect Immun. 1987 Jul;55(7):1652–1656. doi: 10.1128/iai.55.7.1652-1656.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  103. Van Der Ley P., Poolman J. T. Construction of a multivalent meningococcal vaccine strain based on the class 1 outer membrane protein. Infect Immun. 1992 Aug;60(8):3156–3161. doi: 10.1128/iai.60.8.3156-3161.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  104. Verheul A. F., Boons G. J., Van der Marel G. A., Van Boom J. H., Jennings H. J., Snippe H., Verhoef J., Hoogerhout P., Poolman J. T. Minimal oligosaccharide structures required for induction of immune responses against meningococcal immunotype L1, L2, and L3,7,9 lipopolysaccharides determined by using synthetic oligosaccharide-protein conjugates. Infect Immun. 1991 Oct;59(10):3566–3573. doi: 10.1128/iai.59.10.3566-3573.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  105. Verheul A. F., Braat A. K., Leenhouts J. M., Hoogerhout P., Poolman J. T., Snippe H., Verhoef J. Preparation, characterization, and immunogenicity of meningococcal immunotype L2 and L3,7,9 phosphoethanolamine group-containing oligosaccharide-protein conjugates. Infect Immun. 1991 Mar;59(3):843–851. doi: 10.1128/iai.59.3.843-851.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  106. Verheul A. F., Poolman J. T., Snippe H., Verhoef J. The influence of the adjuvant Quil A on the epitope specificity of meningococcal lipopolysaccharide anti-carbohydrate antibodies. Mol Immunol. 1991 Nov;28(11):1193–1200. doi: 10.1016/0161-5890(91)90005-5. [DOI] [PubMed] [Google Scholar]
  107. Verheul A. F., Van Gaans J. A., Wiertz E. J., Snippe H., Verhoef J., Poolman J. T. Meningococcal lipopolysaccharide (LPS)-derived oligosaccharide-protein conjugates evoke outer membrane protein- but not LPS-specific bactericidal antibodies in mice: influence of adjuvants. Infect Immun. 1993 Jan;61(1):187–196. doi: 10.1128/iai.61.1.187-196.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  108. Verheul A. F., Versteeg A. A., De Reuver M. J., Jansze M., Snippe H. Modulation of the immune response to pneumococcal type 14 capsular polysaccharide-protein conjugates by the adjuvant Quil A depends on the properties of the conjugates. Infect Immun. 1989 Apr;57(4):1078–1083. doi: 10.1128/iai.57.4.1078-1083.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  109. Virji M., Weiser J. N., Lindberg A. A., Moxon E. R. Antigenic similarities in lipopolysaccharides of Haemophilus and Neisseria and expression of a digalactoside structure also present on human cells. Microb Pathog. 1990 Dec;9(6):441–450. doi: 10.1016/0882-4010(90)90062-u. [DOI] [PubMed] [Google Scholar]
  110. Waage A., Brandtzaeg P., Halstensen A., Kierulf P., Espevik T. The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin 6, interleukin 1, and fatal outcome. J Exp Med. 1989 Jan 1;169(1):333–338. doi: 10.1084/jem.169.1.333. [DOI] [PMC free article] [PubMed] [Google Scholar]
  111. Waage A., Halstensen A., Shalaby R., Brandtzaeg P., Kierulf P., Espevik T. Local production of tumor necrosis factor alpha, interleukin 1, and interleukin 6 in meningococcal meningitis. Relation to the inflammatory response. J Exp Med. 1989 Dec 1;170(6):1859–1867. doi: 10.1084/jem.170.6.1859. [DOI] [PMC free article] [PubMed] [Google Scholar]
  112. Wahdan M. H., Rizk F., el-Akkad A. M., el-Ghoroury A. A., Hablas R., Girgis N. I., Amer A., Boctar W., Sippel J. E., Gotschlich E. C. A controlled field trial of a serogroup A meningococcal polysaccharide vaccine. Bull World Health Organ. 1973 Jun;48(6):667–673. [PMC free article] [PubMed] [Google Scholar]
  113. Woods J. P., Cannon J. G. Variation in expression of class 1 and class 5 outer membrane proteins during nasopharyngeal carriage of Neisseria meningitidis. Infect Immun. 1990 Feb;58(2):569–572. doi: 10.1128/iai.58.2.569-572.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  114. Yamasaki R., Schneider H., Griffiss J. M., Mandrell R. Epitope expression of gonococcal lipooligosaccharide (LOS). Importance of the lipoidal moiety for expression of an epitope that exists in the oligosaccharide moiety of LOS. Mol Immunol. 1988 Aug;25(8):799–809. doi: 10.1016/0161-5890(88)90116-2. [DOI] [PubMed] [Google Scholar]
  115. Zollinger W. D., Mandrell R. E., Griffiss J. M., Altieri P., Berman S. Complex of meningococcal group B polysaccharide and type 2 outer membrane protein immunogenic in man. J Clin Invest. 1979 May;63(5):836–848. doi: 10.1172/JCI109383. [DOI] [PMC free article] [PubMed] [Google Scholar]
  116. Zollinger W. D., Mandrell R. E. Outer-membrane protein and lipopolysaccharide serotyping of Neisseria meningitidis by inhibition of a solid-phase radioimmunoassay. Infect Immun. 1977 Nov;18(2):424–433. doi: 10.1128/iai.18.2.424-433.1977. [DOI] [PMC free article] [PubMed] [Google Scholar]
  117. Zollinger W. D., Mandrell R. E. Type-specific antigens of group A Neisseria meningitidis: lipopolysaccharide and heat-modifiable outer membrane proteins. Infect Immun. 1980 May;28(2):451–458. doi: 10.1128/iai.28.2.451-458.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Microbiological Reviews are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES